-1(1).png)
.png)
.png)
ABSTRACT
Body weight (BW), body fat ratio (BFR) and serum lipid profile were evaluated in 50 obese patients; 20 treated with a 1100Kcal Standard low calorie diet (group D) and 30 treated with dexfenfluramine (DF) along with the same Standard low calorie diet (group DDF). The patients in each group were followed monthly. At the end of the four months, the mean body weight decreased from 87.4±10 to 85.2±10 kg with a mean decrement of 2.2 kg corresponding to the decrement 2.4±2.6 % of initial body weight in group D. in four months the mean body weight decreased from 98.1±1.15 to 86.3±14 kg with a mean decrement of 11.8 kg corresponding to the 11.9±4.0 % of initial body weight in group DDF. Most of the weight loss was fat in both groups. Mean fat loss was 1.5±0.3 kg in group D and 9.4±4.8 kg in group DDF. After four months, DF was discontinued and both groups were followed on diet alone. However there were drop-outs in group DDF and only 21 of the patients in this group could be followed for six months. Drop-outs increased in number and only 10 patients in group D and 11 patients from group DDF could be evaluated at the end of eight months. Mean weight regain in groups D and DDF was 0.3±0.4 kg and 1.311.0 kg respectively at the end of the sixth month. Further weight gains of 0.3±0.2 kg and 1.911.2 kg were observed respectively in groups D and DDF by the eight month. None of the patients experienced any important side effects that would necessitate the discontinuation of DF. DF is a well tolerated drug that effectively induces weight loss. However, weight regain is a major problem after discontinuing the treatment and longer courses of therapy may be taken into consideration.
Body weight (BW), body fat ratio (BFR) and serum lipid profile were evaluated in 50 obese patients; 20 treated with a 1100Kcal Standard low calorie diet (group D) and 30 treated with dexfenfluramine (DF) along with the same Standard low calorie diet (group DDF). The patients in each group were followed monthly. At the end of the four months, the mean body weight decreased from 87.4±10 to 85.2±10 kg with a mean decrement of 2.2 kg corresponding to the decrement 2.4±2.6 % of initial body weight in group D. in four months the mean body weight decreased from 98.1±1.15 to 86.3±14 kg with a mean decrement of 11.8 kg corresponding to the 11.9±4.0 % of initial body weight in group DDF. Most of the weight loss was fat in both groups. Mean fat loss was 1.5±0.3 kg in group D and 9.4±4.8 kg in group DDF. After four months, DF was discontinued and both groups were followed on diet alone. However there were drop-outs in group DDF and only 21 of the patients in this group could be followed for six months. Drop-outs increased in number and only 10 patients in group D and 11 patients from group DDF could be evaluated at the end of eight months. Mean weight regain in groups D and DDF was 0.3±0.4 kg and 1.311.0 kg respectively at the end of the sixth month. Further weight gains of 0.3±0.2 kg and 1.911.2 kg were observed respectively in groups D and DDF by the eight month. None of the patients experienced any important side effects that would necessitate the discontinuation of DF. DF is a well tolerated drug that effectively induces weight loss. However, weight regain is a major problem after discontinuing the treatment and longer courses of therapy may be taken into consideration.